Global Lung Cancer Diagnostics Market Overview:
Global Lung Cancer Diagnostics Market Is Expected to Grow at A Significant Growth Rate, And the Forecast Period Is 2025-2032, Considering the Base Year As 2024.
Global Lung Cancer Diagnostics Market Report 2025 comes with the extensive industry analysis with development components, patterns, flows and sizes. The report also calculates present and past market values to forecast potential market management through the forecast period between 2025-2032.This research study of Lung Cancer Diagnostics involved the extensive usage of both primary and secondary data sources. This includes the study of various parameters affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry.
Scope of the Lung Cancer Diagnostics Market:
The Lung Cancer Diagnostics Market Research report incorporates value chain analysis for each of the product type. Value chain analysis offers in-depth information about value addition at each stage.The study includes drivers and restraints for Lung Cancer Diagnostics Market along with their impact on demand during the forecast period. The study also provides key market indicators affecting thegrowth of the market. Research report includes major key player analysis with shares of each player inside market, growth rate and market attractiveness in different endusers/regions. Our study Lung Cancer Diagnostics Market helps user to make precise decision in order to expand their market presence and increase market share.
By Type, Lung Cancer Diagnostics market has been segmented into:
Imaging Tests
Sputum Cytology
Molecular Tests
Biopsy
and Other Tests
By Application, Lung Cancer Diagnostics market has been segmented into:
Non-Small-Cell Lung Cancer (NSCLC)
and Small-Cell Lung Cancer (SCLC
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Lung Cancer Diagnostics market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the Lung Cancer Diagnostics market.
Top Key Players Covered in Lung Cancer Diagnostics market are:
Myriad Genetics Inc.
F. Hoffmann-La Roche AG
Biocartis NV
Epigenomics AG
Biodesix Inc.
Exosome Diagnostics Inc.
Admera Health
Dr Lal PathLabs Ltd.
Guardant Health Inc.
Oncimmune Holding PLC
Blueprint Genetics OY
CellMax Life Inc.
Circulogene
BGI Genomics Co Ltd.
Inivata Ltd.
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Industry Dynamics and Opportunity Analysis
3.1.1 Growth Drivers
3.1.2 Limiting Factors
3.1.3 Growth Opportunities
3.1.4 Challenges and Risks
3.2 Market Trend Analysis
3.3 Strategic Pestle Overview
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Mapping
3.6 Regulatory Framework
3.7 Princing Trend Analysis
3.8 Patent Analysis
3.9 Technology Evolution
3.10 Investment Pockets
3.11 Import-Export Analysis
Chapter 4: Lung Cancer Diagnostics Market Type
4.1 Lung Cancer Diagnostics Market Snapshot and Growth Engine
4.2 Lung Cancer Diagnostics Market Overview
4.3 Imaging Tests
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.3.3 Imaging Tests: Geographic Segmentation Analysis
4.4 Sputum Cytology
4.4.1 Introduction and Market Overview
4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.4.3 Sputum Cytology: Geographic Segmentation Analysis
4.5 Molecular Tests
4.5.1 Introduction and Market Overview
4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.5.3 Molecular Tests: Geographic Segmentation Analysis
4.6 Biopsy
4.6.1 Introduction and Market Overview
4.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.6.3 Biopsy: Geographic Segmentation Analysis
4.7 and Other Tests
4.7.1 Introduction and Market Overview
4.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.7.3 and Other Tests: Geographic Segmentation Analysis
Chapter 5: Lung Cancer Diagnostics Market Application
5.1 Lung Cancer Diagnostics Market Snapshot and Growth Engine
5.2 Lung Cancer Diagnostics Market Overview
5.3 Non-Small-Cell Lung Cancer (NSCLC)
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.3.3 Non-Small-Cell Lung Cancer (NSCLC): Geographic Segmentation Analysis
5.4 and Small-Cell Lung Cancer (SCLC
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.4.3 and Small-Cell Lung Cancer (SCLC: Geographic Segmentation Analysis
Chapter 6: Company Profiles and Competitive Analysis
6.1 Competitive Landscape
6.1.1 Competitive Benchmarking
6.1.2 Lung Cancer Diagnostics Market Share by Manufacturer (2025)
6.1.3 Concentration Ratio(CR5)
6.1.4 Heat Map Analysis
6.1.5 Mergers and Acquisitions
6.2 MYRIAD GENETICS
6.2.1 Company Overview
6.2.2 Key Executives
6.2.3 Company Snapshot
6.2.4 Operating Business Segments
6.2.5 Product Portfolio
6.2.6 Business Performance
6.2.7 Key Strategic Moves and Recent Developments
6.3 INC.; F. HOFFMANN-LA ROCHE AG; BIOCARTIS NV; EPIGENOMICS AG; BIODESIX
6.4 INC.; EXOSOME DIAGNOSTICS
6.5 INC.; ADMERA HEALTH; DR LAL PATHLABS LTD.; GUARDANT HEALTH
6.6 INC.; ONCIMMUNE HOLDING PLC; BLUEPRINT GENETICS OY; CELLMAX LIFE
6.7 INC.; CIRCULOGENE; BGI GENOMICS CO LTD.; INIVATA LTD.
Chapter 7: Global Lung Cancer Diagnostics Market By Region
7.1 Overview
7.2. North America Lung Cancer Diagnostics Market
7.2.1 Historic and Forecasted Market Size by Segments
7.2.2 Historic and Forecasted Market Size By Type
7.2.2.1 Imaging Tests
7.2.2.2 Sputum Cytology
7.2.2.3 Molecular Tests
7.2.2.4 Biopsy
7.2.2.5 and Other Tests
7.2.3 Historic and Forecasted Market Size By Application
7.2.3.1 Non-Small-Cell Lung Cancer (NSCLC)
7.2.3.2 and Small-Cell Lung Cancer (SCLC
7.2.4 Historic and Forecast Market Size by Country
7.2.4.1 US
7.2.4.2 Canada
7.2.4.3 Mexico
7.3. Eastern Europe Lung Cancer Diagnostics Market
7.3.1 Historic and Forecasted Market Size by Segments
7.3.2 Historic and Forecasted Market Size By Type
7.3.2.1 Imaging Tests
7.3.2.2 Sputum Cytology
7.3.2.3 Molecular Tests
7.3.2.4 Biopsy
7.3.2.5 and Other Tests
7.3.3 Historic and Forecasted Market Size By Application
7.3.3.1 Non-Small-Cell Lung Cancer (NSCLC)
7.3.3.2 and Small-Cell Lung Cancer (SCLC
7.3.4 Historic and Forecast Market Size by Country
7.3.4.1 Russia
7.3.4.2 Bulgaria
7.3.4.3 The Czech Republic
7.3.4.4 Hungary
7.3.4.5 Poland
7.3.4.6 Romania
7.3.4.7 Rest of Eastern Europe
7.4. Western Europe Lung Cancer Diagnostics Market
7.4.1 Historic and Forecasted Market Size by Segments
7.4.2 Historic and Forecasted Market Size By Type
7.4.2.1 Imaging Tests
7.4.2.2 Sputum Cytology
7.4.2.3 Molecular Tests
7.4.2.4 Biopsy
7.4.2.5 and Other Tests
7.4.3 Historic and Forecasted Market Size By Application
7.4.3.1 Non-Small-Cell Lung Cancer (NSCLC)
7.4.3.2 and Small-Cell Lung Cancer (SCLC
7.4.4 Historic and Forecast Market Size by Country
7.4.4.1 Germany
7.4.4.2 UK
7.4.4.3 France
7.4.4.4 The Netherlands
7.4.4.5 Italy
7.4.4.6 Spain
7.4.4.7 Rest of Western Europe
7.5. Asia Pacific Lung Cancer Diagnostics Market
7.5.1 Historic and Forecasted Market Size by Segments
7.5.2 Historic and Forecasted Market Size By Type
7.5.2.1 Imaging Tests
7.5.2.2 Sputum Cytology
7.5.2.3 Molecular Tests
7.5.2.4 Biopsy
7.5.2.5 and Other Tests
7.5.3 Historic and Forecasted Market Size By Application
7.5.3.1 Non-Small-Cell Lung Cancer (NSCLC)
7.5.3.2 and Small-Cell Lung Cancer (SCLC
7.5.4 Historic and Forecast Market Size by Country
7.5.4.1 China
7.5.4.2 India
7.5.4.3 Japan
7.5.4.4 South Korea
7.5.4.5 Malaysia
7.5.4.6 Thailand
7.5.4.7 Vietnam
7.5.4.8 The Philippines
7.5.4.9 Australia
7.5.4.10 New Zealand
7.5.4.11 Rest of APAC
7.6. Middle East & Africa Lung Cancer Diagnostics Market
7.6.1 Historic and Forecasted Market Size by Segments
7.6.2 Historic and Forecasted Market Size By Type
7.6.2.1 Imaging Tests
7.6.2.2 Sputum Cytology
7.6.2.3 Molecular Tests
7.6.2.4 Biopsy
7.6.2.5 and Other Tests
7.6.3 Historic and Forecasted Market Size By Application
7.6.3.1 Non-Small-Cell Lung Cancer (NSCLC)
7.6.3.2 and Small-Cell Lung Cancer (SCLC
7.6.4 Historic and Forecast Market Size by Country
7.6.4.1 Turkiye
7.6.4.2 Bahrain
7.6.4.3 Kuwait
7.6.4.4 Saudi Arabia
7.6.4.5 Qatar
7.6.4.6 UAE
7.6.4.7 Israel
7.6.4.8 South Africa
7.7. South America Lung Cancer Diagnostics Market
7.7.1 Historic and Forecasted Market Size by Segments
7.7.2 Historic and Forecasted Market Size By Type
7.7.2.1 Imaging Tests
7.7.2.2 Sputum Cytology
7.7.2.3 Molecular Tests
7.7.2.4 Biopsy
7.7.2.5 and Other Tests
7.7.3 Historic and Forecasted Market Size By Application
7.7.3.1 Non-Small-Cell Lung Cancer (NSCLC)
7.7.3.2 and Small-Cell Lung Cancer (SCLC
7.7.4 Historic and Forecast Market Size by Country
7.7.4.1 Brazil
7.7.4.2 Argentina
7.7.4.3 Rest of SA
Chapter 8 Analyst Viewpoint and Conclusion
8.1 Recommendations and Concluding Analysis
8.2 Potential Market Strategies
Chapter 9 Research Methodology
9.1 Research Process
9.2 Primary Research
9.3 Secondary Research
Lung Cancer Diagnostics Scope:
|
Report Data
|
Lung Cancer Diagnostics Market
|
|
Lung Cancer Diagnostics Market Size in 2025
|
USD XX million
|
|
Lung Cancer Diagnostics CAGR 2025 - 2032
|
XX%
|
|
Lung Cancer Diagnostics Base Year
|
2024
|
|
Lung Cancer Diagnostics Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
Myriad Genetics Inc., F. Hoffmann-La Roche AG, Biocartis NV, Epigenomics AG, Biodesix Inc., Exosome Diagnostics Inc., Admera Health, Dr Lal PathLabs Ltd., Guardant Health Inc., Oncimmune Holding PLC, Blueprint Genetics OY, CellMax Life Inc., Circulogene, BGI Genomics Co Ltd., Inivata Ltd..
|
|
Key Segments
|
By Type
Imaging Tests
Sputum Cytology
Molecular Tests
Biopsy
and Other Tests
By Applications
Non-Small-Cell Lung Cancer (NSCLC)
and Small-Cell Lung Cancer (SCLC
|
